About this item:

77 Views | 121 Downloads

Author Notes:

See publication for full list of authors.

Correspondence to Louis-Philippe Laurin, Division of Nephrology, Maisonneuve-Rosemont Hospital, 5415, Boulevard de l’Assomption, Montreal (Quebec), Canada H1T 2M4. louis-philippe.laurin@umontreal.ca

JT has additional research funding through the University of Michigan with Complexa Inc., Retrophin Inc., Goldfinch Bio, Vertex Pharmaceuticals, and Pfizer.

TS received additional research support from Mallinckrodt Pharmaceuticals, Bristol-Myers Squibb, and Retrophin, Inc.

MR received research funding from Retrophin, Reata, Advicenne, Roche, and Regulus Therapeutics.

LG-W is a paid consultant for Otsuka Pharmaceuticals.

LPL is a Fonds de recherche du Québec–Santé Junior 1 Scholar.

All the other authors declared no competing interests.

Subjects:

Research Funding:

Funding for the CureGN consortium is provided by UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867 from the National Institute of Diabetes and Digestive and Kidney Diseases.

Patient recruitment is supported by NephCure Kidney International.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Urology & Nephrology
  • immunosuppression
  • membranous nephropathy
  • treatment patterns
  • NEPHROTIC SYNDROME
  • RECEPTOR
  • RITUXIMAB
  • REMISSION
  • TRIAL

Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN)

Tools:

Journal Title:

Kidney International Reports

Volume:

Volume 4, Number 12

Publisher:

, Pages 1725-1734

Type of Work:

Article | Final Publisher PDF

Abstract:

Introduction: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophosphamide (CYC) or calcineurin inhibitor (CNI)–based regimen is recommended as first-line IST. However, the extent to which KDIGO recommendations are adopted in practice remains largely unknown. Methods: We evaluated prescribing practice among patients with primary MN (diagnosed 2010–2018) enrolled in the Cure Glomerulonephropathy Network (CureGN) cohort study. We also evaluated the availability of testing for phospholipase A2 receptor (PLA2R) in the contemporary era. Results: Among 361 patients (324 adults and 37 children) with MN who were IST-naïve at biopsy and had at least 6 months of follow-up, 55% of adults and 58% of children initiated IST <6 months after biopsy. Of these, 1 in 5 had no indication for (i.e., urine protein-to-creatinine ratio [uPCR] <4 g/g) or an apparent contraindication to (i.e., an estimated glomerular filtration rate [eGFR] <30 ml/min per 1.73 m2) IST. As first-line IST, half of treated patients received either CYC (16% of adults; 0% of children) or a CNI (40% and 46%, respectively), whereas 1 in 5 received corticosteroid monotherapy (20% and 27%, respectively) and 1 in 6 rituximab (15% and 15%, respectively). More than 80% of surveyed centers had access to PLA2R testing. Conclusion: These findings suggest that providers are not aware of, or lack confidence in, current KDIGO guidelines for MN. Treatment patterns observed in this cohort might critically inform the drafting of planned updates to KDIGO guidelines.

Copyright information:

© 2019 International Society of Nephrology

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Export to EndNote